Denali Therapeutics Inc(DNLI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.84 | Insider Own | 6.34% | Shs Outstand | 159.8M | Perf Week | 3.27% |
| Market Cap | 3.08B | Forward P/E | - | EPS next Y | -5.27% | Insider Trans | -0.18% | Shs Float | 149.7M | Perf Month | -7.3% |
| Enterprise Value | 2.41B | PEG | - | EPS next Q | -0.32 | Inst Own | 98.08% | Short Float | 10.34% | Perf Quarter | -20.78% |
| Income | -0.51B | P/S | 856.52 | EPS this Y | 24.39% | Inst Trans | 2.36% | Short Ratio | 9.86 | Perf Half Y | 3.71% |
| Sales | 0.00B | P/B | 3.69 | EPS next 5Y | 15.72% | ROA | -44.01% | Short Interest | 15.48M | Perf YTD | 16.84% |
| Book/sh | 5.23 | P/C | 4.34 | EPS past 3/5Y | -4.56% - | ROE | -54.93% | 52W High | -29.34% ($27.30) | Perf Year | 14.01% |
| Cash/sh | 4.44 | P/FCF | - | Sales past 3/5Y | - | ROIC | -59.29% | 52W Low | 40.29% ($13.75) | Perf 3Y | 5.99% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -1.07% | Gross Margin | -318.04% | Volatility(W/M) | 2.92% 4.02% | Perf 5Y | -60.57% |
| Dividend TTM | - | EV/Sales | 669.63 | Sales Y/Y TTM | - | Oper. Margin | -15058.19% | ATR (14) | 0.78 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.32 | EPS Q/Q | 5.93% | Profit Margin | -14191.2% | RSI (14) | 48.53 | Recom | 1.15 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.37 | Sales Q/Q | - | SMA20 | 2.05% ($18.9) | Beta | 1.07 | Target Price | $35.5 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/11/3 | SMA50 | -7.65% ($20.89) | Rel Volume | 1.01 | Prev Close | $19.22 |
| Employees | 503 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | -32.55% 67.29% | SMA200 | -9.12% ($21.23) | Avg Volume(3M) | 1.57M | Price | $19.29 |
| IPO | 2017/12/8 | Option/Short | Yes/Yes | Trades | 14529 | Volume | 1,586,303 | Change | 0.36% |
A clinical-stage biotech company developing therapies for neurological disorders. Leveraging blood-brain barrier delivery technology, the company is developing treatments for neurodegenerative diseases such as Parkinson's disease and ALS (Lou Gehrig's disease), and is drawing attention for its clinical progress. It is a biotech firm specializing in therapeutics for neurological conditions.
Over the past 1 year, roughly in the middle
29% below its 1-year high.
Traded about as much as usual. That is 101% of its average volume.
Next earnings report: November 3
5 days to go.
DNLI has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +24.4% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $85,652. Peers typically go for $1,953.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -60.6%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 98.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #74 of 594 in the industry
Based on market cap of $3B.
IRON#71 Disc Medicine Inc $3B PER - 
DYN#72 Dyne Therapeutics Inc $3B PER - 
TLX#73 Telix Pharmaceuticals Ltd ADR $3B PER 99.0 DNLI#74 Denali Therapeutics Inc $3B PER - 
NRIX#75 Nurix Therapeutics Inc $3B PER 11.8 
FAQ
What kind of company is DNLI?
DNLI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DNLI?
The market cap of DNLI is approximately $3.1B, ranking 1,744 within its sector.
What is the 52-week high and low for DNLI?
DNLI has recorded a 52-week high of $27.30 and a low of $13.75.
